drugset / Trial / NCT01213355
Scopolamine Challenge Study
RandomizedCrossoverDouble-blindOther
Summary
It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive impairments in healthy adults subjects.
Timeline
- Start
- 2011-04
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Donepezil | Small molecule | 10 mg | Oral |
| Subject | PF-05212377 | Small molecule | 5 mg | Oral |
| Subject | PF-05212377 | Small molecule | 20 mg | Oral |
| Subject | PF-05212377 | Small molecule | 60 mg | Oral |
| Background | Scopolamine | Unknown | 0.5 mg | Subcutaneous |
Indications
No indication recorded.